As per the information provided by the Abbott company officials, finally the U. S. Food and Drug Administration (FDA) has proved their molecular investigative test plans.

While giving more details about their approved plans, the Company officials claimed that following the new test diagram, a new anaplastic lymphoma kinase (ALK) method would be invented by them.

However, the new method would for sure help them to investigate the non small cell lung cancer (NSCLC) genes in the Fishes.

Meanwhile, the company officials auxiliary asserted that the Vysis ALK trawl examination would be using the Company's fluorescence fish hybridization machinery to distinguish the ALK gene rearrangements procedures on the
2p23 genetic material.

Sharing his views about the new test method, the Company's molecular diagnostics business head, Stafford O'Kelly, commented that if the test works according to their planned strategies, then it surely would create a history in the fishing industry.

In the meantime, the FDA officials added that unquestionably this test success velocity was linked with the decreases of cancer risks among the NSCLC patients.

He added, "We expect that many patients newly diagnosed with NSCLC will want to ask their doctors about the potential benefits of this new genetic test".